Healthcare
Kyowa Kirin Co., Ltd.(KYKOF)
Live Price
Offline$14.43
+0.00% today
1Y Change
-3.52%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $1.25T
- Revenue Growth
- +0.3%
- EPS Growth
- +13.4%
- Dividend Yield
- 2.6%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kyowa Kirin Co., Ltd. (KYKOF) is a Healthcare stock with a market cap of $1.25T and listed on OTC. The stock last traded around $14.43 and down 3.5% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +0.3%, EPS growth of +13.4%, a dividend yield of 2.6%. What stands out right now is revenue +0.3%, EPS +13.4%, free cash flow +257.7% with operating margin 20.6% and ROIC 8.5%. The dividend matters to the case here, with a current yield around 2.6%. Valuation is more restrained than many high-expectation growth names at P/E 18.7 and price/sales 2.5. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines KYKOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.3% vs +7.6% peer median
Operating Margin
Near sector median
+20.6% vs +19.4% peer median
P/E
Below sector median
18.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +0.3% and EPS at +13.4%, with operating margin around 20.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.4% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.0% | -4.2% | -4.2% |
2026 Feb 9, 2026 | +60.9% | +0.0% | +0.0% | -20.9% |
2025 Jul 31, 2025 | -39.4% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
KYKOF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KYKOF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KYKOF Max Drawdown
-31.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KYKOF and SPY.
Company Overview
Kyowa Kirin Co., Ltd.
Other OTC
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
- Leadership
- Abdul Hafeez Mullick
- IPO Date
- Aug 17, 2012
- Employees
- 5.7k
- Street Address
- Otemachi Financial City Grand Cube
- Mailing
- Tokyo, 100-0004
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 5205 7200
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.7
- EV/EBITDA
- 8.3
- Price/Sales
- 2.5
- Price/Book
- 1.4
Growth
- Revenue
- +0.3%
- EPS
- +13.4%
- Free Cash Flow
- +257.7%
Profitability
- Gross Margin
- 74.2%
- Operating Margin
- 20.6%
- Net Margin
- 13.5%
- ROE
- 7.9%
- ROIC
- 8.5%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 2.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.